Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 U.S. HHS Seeks Stakeholder COVID-19 Countermeasures | Contract Pharma
Breaking News

U.S. HHS Seeks Stakeholder COVID-19 Countermeasures

Establishes portal for available medical countermeasures in development

The U.S. Department of Health & Human Services is providing a portal for the COVID-19 medical countermeasures task force as a single point of entry for the submission of market research packages and meeting requests from interested stakeholders.

The U.S. government, in response to the COVID-19 outbreak, is seeking information from stakeholders on available medical countermeasures in development, particularly products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform.

The submission requires a brief product or technology description, along with a slide deck, manuscript, publications, or other non-confidential information. It also notes that any information presented as market research, submission is no guarantee of a meeting or funding and will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure R&D. Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed.

Register here: https://www.medicalcountermeasures.gov/App/CreateUserWizard.aspx

 

 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters